AU543804B2
(en)
*
|
1980-10-31 |
1985-05-02 |
Takeda Chemical Industries Ltd. |
Amides having bicyclic substituents on nitrogen
|
US4766110A
(en)
*
|
1981-08-21 |
1988-08-23 |
Ryan James W |
Novel complex amido and imido derivatives of carboxyalkyl peptides
|
DE3303112A1
(de)
*
|
1983-01-31 |
1984-08-09 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racemattrennung optisch aktiver bicyclischer imino-(alpha)-carbonsaeuren
|
US4840772A
(en)
*
|
1983-06-02 |
1989-06-20 |
Schering Corporation |
Antiglaucoma compositions and methods
|
US4678800A
(en)
*
|
1984-06-15 |
1987-07-07 |
Ciba-Geigy Corporation |
Gamma-r-glutamoyl derivatives
|
US4762821A
(en)
*
|
1985-03-22 |
1988-08-09 |
Syntex (U.S.A.) Inc. |
N',N"-dialkylguanidino dipeptides
|
DE3518514A1
(de)
*
|
1985-05-23 |
1986-11-27 |
Hoechst Ag, 6230 Frankfurt |
Neue derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
|
DE3641451A1
(de)
*
|
1986-12-04 |
1988-06-16 |
Hoechst Ag |
Derivate bicyclischer aminocarbonsaeuren, verfahren und zwischenprodukte zu deren herstellung sowie deren verwendung
|
KR930004646B1
(ko)
*
|
1986-12-09 |
1993-06-02 |
다나베 세이야꾸 가부시끼가이샤 |
심기능 부전의 예방 및 치료제
|
DE3731085A1
(de)
*
|
1987-09-16 |
1989-04-06 |
Hoechst Ag |
Neue aminosaeureester, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
|
US4927807A
(en)
*
|
1987-10-06 |
1990-05-22 |
Abbott Laboratories |
Glaucoma treatment
|
US5346887A
(en)
*
|
1987-10-06 |
1994-09-13 |
Abbott Laboratories |
Glaucoma treatment
|
US5036051A
(en)
*
|
1987-10-06 |
1991-07-30 |
Abbott Laboratories |
Glaucoma treatment
|
HU904967D0
(en)
*
|
1988-04-22 |
1991-01-28 |
Hoechst Ag |
Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
|
US5059589A
(en)
*
|
1988-09-08 |
1991-10-22 |
Abbott Laboratories |
Glaucoma treatment
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US5977160A
(en)
*
|
1992-04-10 |
1999-11-02 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US7056935B2
(en)
*
|
1995-06-07 |
2006-06-06 |
Gpi Nil Holdings, Inc. |
Rotamase enzyme activity inhibitors
|
US5859031A
(en)
|
1995-06-07 |
1999-01-12 |
Gpi Nil Holdings, Inc. |
Small molecule inhibitors of rotamase enzyme activity
|
US20020042377A1
(en)
*
|
1995-06-07 |
2002-04-11 |
Steiner Joseph P. |
Rotamase enzyme activity inhibitors
|
US5801197A
(en)
*
|
1995-10-31 |
1998-09-01 |
Gpi Nil Holdings, Inc. |
Rotamase enzyme activity inhibitors
|
US5801187A
(en)
|
1996-09-25 |
1998-09-01 |
Gpi-Nil Holdings, Inc. |
Heterocyclic esters and amides
|
US6218424B1
(en)
*
|
1996-09-25 |
2001-04-17 |
Gpi Nil Holdings, Inc. |
Heterocyclic ketone and thioester compounds and uses
|
US5786378A
(en)
*
|
1996-09-25 |
1998-07-28 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioesters
|
US6187784B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Pipecolic acid derivative hair growth compositions and uses
|
US6271244B1
(en)
|
1998-06-03 |
2001-08-07 |
Gpi Nil Holdings, Inc. |
N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
|
US5945441A
(en)
|
1997-06-04 |
1999-08-31 |
Gpi Nil Holdings, Inc. |
Pyrrolidine carboxylate hair revitalizing agents
|
US6187796B1
(en)
|
1998-06-03 |
2001-02-13 |
Gpi Nil Holdings, Inc. |
Sulfone hair growth compositions and uses
|
US20010049381A1
(en)
*
|
1997-06-04 |
2001-12-06 |
Gpl Nil Holdings, Inc., |
Pyrrolidine derivative hair growth compositions and uses
|
US6274602B1
(en)
|
1998-06-03 |
2001-08-14 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioester and ketone hair growth compositions and uses
|
US6331537B1
(en)
|
1998-06-03 |
2001-12-18 |
Gpi Nil Holdings, Inc. |
Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
|
US6172087B1
(en)
|
1998-06-03 |
2001-01-09 |
Gpi Nil Holding, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
JP2002516843A
(ja)
|
1998-06-03 |
2002-06-11 |
ジー・ピー・アイ ニイル ホールディングス インコーポレィティッド |
ヘテロサイクリックエステルおよびアミド発毛組成物およびその使用
|
US6429215B1
(en)
|
1998-06-03 |
2002-08-06 |
Gpi Nil Holdings, Inc. |
N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
|
US6218423B1
(en)
|
1998-08-14 |
2001-04-17 |
Gpi Nil Holdings, Inc. |
Pyrrolidine derivatives for vision and memory disorders
|
US7338976B1
(en)
|
1998-08-14 |
2008-03-04 |
Gpi Nil Holdings, Inc. |
Heterocyclic esters or amides for vision and memory disorders
|
US6506788B1
(en)
|
1998-08-14 |
2003-01-14 |
Gpi Nil Holdings, Inc. |
N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
|
US6399648B1
(en)
|
1998-08-14 |
2002-06-04 |
Gpi Nil Holdings, Inc. |
N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
|
US6333340B1
(en)
|
1998-08-14 |
2001-12-25 |
Gpi Nil Holdings, Inc. |
Small molecule sulfonamides for vision and memory disorders
|
US6339101B1
(en)
|
1998-08-14 |
2002-01-15 |
Gpi Nil Holdings, Inc. |
N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
|
US6376517B1
(en)
|
1998-08-14 |
2002-04-23 |
Gpi Nil Holdings, Inc. |
Pipecolic acid derivatives for vision and memory disorders
|
US6335348B1
(en)
|
1998-08-14 |
2002-01-01 |
Gpi Nil Holdings, Inc. |
Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
|
US6337340B1
(en)
|
1998-08-14 |
2002-01-08 |
Gpi Nil Holdings, Inc. |
Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
|
US6395758B1
(en)
|
1998-08-14 |
2002-05-28 |
Gpi Nil Holdings, Inc. |
Small molecule carbamates or ureas for vision and memory disorders
|
US6384056B1
(en)
|
1998-08-14 |
2002-05-07 |
Gpi Nil Holdings, Inc. |
Heterocyclic thioesters or ketones for vision and memory disorders
|
US6462072B1
(en)
|
1998-09-21 |
2002-10-08 |
Gpi Nil Holdings, Inc. |
Cyclic ester or amide derivatives
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
RU2276997C2
(ru)
*
|
1999-08-30 |
2006-05-27 |
Санофи-Авентис Дойчланд Гмбх |
Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
|
AU7604400A
(en)
*
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
|
US20030113330A1
(en)
*
|
1999-11-08 |
2003-06-19 |
Uhal Bruce D. |
Methods for treating pulmonary fibrosis
|
JP2003523330A
(ja)
*
|
2000-02-04 |
2003-08-05 |
チルドレンズ・ホスピタル・リサーチ・ファウンデイション |
アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
|
US8088060B2
(en)
|
2000-03-15 |
2012-01-03 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
US9522217B2
(en)
|
2000-03-15 |
2016-12-20 |
Orbusneich Medical, Inc. |
Medical device with coating for capturing genetically-altered cells and methods for using same
|
US20070141107A1
(en)
*
|
2000-03-15 |
2007-06-21 |
Orbusneich Medical, Inc. |
Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
|
US20020142970A1
(en)
*
|
2000-10-10 |
2002-10-03 |
Vaughan Douglas E. |
Method for treating or preventing cardiovascular disease via administration of an ace inhibitor
|
EP1386165B1
(en)
|
2000-12-14 |
2011-11-02 |
The Brigham And Women's Hospital, Inc. |
Inflammatory markers for detection and prevention of diabetes mellitus
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
KR20040100835A
(ko)
*
|
2001-02-15 |
2004-12-02 |
킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 |
안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
AR036187A1
(es)
*
|
2001-07-24 |
2004-08-18 |
Adir |
Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
US7101569B2
(en)
*
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
US20030190350A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
US7107198B2
(en)
*
|
2001-11-02 |
2006-09-12 |
Sun Microsystems, Inc. |
Automatic generation of reduced-size circuit models including inductive interaction
|
CA2363658C
(en)
*
|
2001-11-21 |
2005-12-13 |
Brantford Chemicals Inc. |
Improved process for the preparation of ramipril
|
US6407262B1
(en)
*
|
2001-11-21 |
2002-06-18 |
Brantford Chemicals Inc. |
Process for the preparation of Ramipril
|
JP2005519098A
(ja)
*
|
2002-03-01 |
2005-06-30 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
変形性関節症の治療方法
|
DK3072978T3
(en)
|
2002-05-09 |
2018-09-17 |
Brigham & Womens Hospital Inc |
: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
|
PL375713A1
(en)
|
2002-08-19 |
2005-12-12 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
MXPA05006399A
(es)
*
|
2002-12-16 |
2006-01-27 |
King Pharmaceuticals Inc |
Metodos y formas de dosificacion para reducir los ataques al corazon en un individuo hipertenso con un diuretico o una combinacion de un diuretico y un inhibidor de la eca.
|
US9492388B2
(en)
|
2002-12-20 |
2016-11-15 |
St. James Associates Llc/Faber Research Series |
Coated particles for sustained-release pharmaceutical administration
|
CL2004000366A1
(es)
*
|
2003-02-26 |
2005-01-07 |
Pharmacia Corp Sa Organizada B |
USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
|
CL2004000544A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
|
BRPI0409428A
(pt)
*
|
2003-04-15 |
2006-04-18 |
Warner Lambert Co |
derivados de prolina bicìclicos [c]-fundidos e a sua utilização para tratar estados artrìticos
|
WO2004092132A1
(en)
*
|
2003-04-15 |
2004-10-28 |
Warner-Lambert Company Llc |
[b]-fused bicyclic proline derivatives and their use for treating arthritic conditions
|
AU2004242777B2
(en)
*
|
2003-05-30 |
2011-05-12 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
WO2005002548A1
(en)
*
|
2003-06-26 |
2005-01-13 |
Teva Pharmaceutical Industries Ltd. |
Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
US7491743B2
(en)
|
2003-08-29 |
2009-02-17 |
President And Fellows Of Harvard College |
Inhibitors of cellular necrosis
|
CA2549236C
(en)
|
2003-12-05 |
2017-06-13 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
ZA200605383B
(en)
*
|
2003-12-29 |
2008-06-25 |
Sepracor Inc |
Pyrrole and pyrazole daao inhibitors
|
AU2005205251B2
(en)
*
|
2004-01-19 |
2008-07-03 |
Lupin Limited |
Process for crystallization of Ramipril and preparation of a hydrated form thereof
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
EP2343553A1
(en)
|
2004-10-06 |
2011-07-13 |
The Brigham and Women's Hospital |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
EP1817007A2
(en)
*
|
2004-11-05 |
2007-08-15 |
King Pharmaceuticals Research and Development Inc. |
Stabilized individually coated ramipril particles, compositions and methods
|
NZ560386A
(en)
*
|
2005-01-31 |
2009-12-24 |
Mylan Lab Inc |
Pharmaceutical composition comprising hydroxylated nebivolol
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
MX2008000250A
(es)
|
2005-07-06 |
2008-03-19 |
Sepracor Inc |
Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
|
WO2007030375A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Children's Hospital Medical Center |
Lysosomal acid lipase therapy for nafld and related diseases
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
KR101329112B1
(ko)
*
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
KR101381768B1
(ko)
*
|
2006-01-06 |
2014-04-07 |
선오비온 파마슈티컬스 인코포레이티드 |
테트랄론-기재 모노아민 재흡수 저해제
|
NZ569630A
(en)
*
|
2006-01-06 |
2011-09-30 |
Sepracor Inc |
Cycloalkylamines as monoamine reuptake inhibitors
|
CL2007000667A1
(es)
*
|
2006-03-14 |
2008-03-14 |
Ranbaxi Lab Ltd |
Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
|
PT2816024T
(pt)
|
2006-03-31 |
2017-10-20 |
Sunovion Pharmaceuticals Inc |
Aminas quirais
|
US20070232680A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Vijayabhaskar Bolugoddu |
Preparation of ramipril and stable pharmaceutical compositions
|
BRPI0710172A2
(pt)
*
|
2006-04-19 |
2011-08-23 |
Teva Pharma |
composição farmacêutica estável de ácido carboxìlico derivado de 2-aza-biciclo[3,3,0]-octana-3
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
WO2007146229A2
(en)
*
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
US7884124B2
(en)
*
|
2006-06-30 |
2011-02-08 |
Sepracor Inc. |
Fluoro-substituted inhibitors of D-amino acid oxidase
|
US7579370B2
(en)
*
|
2006-06-30 |
2009-08-25 |
Sepracor Inc. |
Fused heterocycles
|
JP2009543773A
(ja)
*
|
2006-07-14 |
2009-12-10 |
ランバクシー ラボラトリーズ リミテッド |
HMG−CoAレダクターゼ阻害剤の多形体及びその使用
|
JP2010501604A
(ja)
*
|
2006-08-28 |
2010-01-21 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
グルコースレベルを低下させる方法
|
US20080082066A1
(en)
*
|
2006-10-02 |
2008-04-03 |
Weyerhaeuser Co. |
Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
|
GB0624090D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amine salts
|
GB0624084D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril amino acid salts
|
EP2094643B1
(en)
|
2006-12-01 |
2012-02-29 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
GB0624087D0
(en)
*
|
2006-12-01 |
2007-01-10 |
Selamine Ltd |
Ramipril combination salt
|
WO2008089453A2
(en)
|
2007-01-18 |
2008-07-24 |
Sepracor Inc. |
Inhibitors of d-amino acid oxidase
|
US7902252B2
(en)
*
|
2007-01-18 |
2011-03-08 |
Sepracor, Inc. |
Inhibitors of D-amino acid oxidase
|
WO2008131224A2
(en)
|
2007-04-18 |
2008-10-30 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
CA2688493C
(en)
|
2007-05-31 |
2016-04-19 |
Sepracor Inc. |
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
|
EP2211906A2
(en)
*
|
2007-11-07 |
2010-08-04 |
Janssen Pharmaceutica, N.V. |
Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
|
GB2462022B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
US20100120740A1
(en)
*
|
2008-08-07 |
2010-05-13 |
Sepracor Inc. |
Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
|
US20110034434A1
(en)
*
|
2009-08-07 |
2011-02-10 |
Sepracor Inc. |
Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
|
EP2531163A1
(en)
|
2010-02-01 |
2012-12-12 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and preventon of restenosis
|
CA2795053A1
(en)
|
2010-03-31 |
2011-10-06 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
CA2800520A1
(en)
|
2010-04-08 |
2011-10-13 |
The Hospital For Sick Children |
Use of remote ischemic conditioning for traumatic injury
|
BR112014001283A2
(pt)
|
2011-07-18 |
2017-02-21 |
Critical Care Diagnostics Inc |
métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
|
WO2013030725A1
(en)
|
2011-08-26 |
2013-03-07 |
Wockhardt Limited |
Methods for treating cardiovascular disorders
|
CA2873214C
(en)
|
2012-05-11 |
2021-02-16 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
EP2879666B1
(en)
|
2012-08-01 |
2020-04-08 |
Tavakoli, Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
WO2014145022A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Hybrid necroptosis inhibitors
|
CA2907765C
(en)
|
2013-03-21 |
2021-07-06 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
WO2014170786A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
CA3003159A1
(en)
|
2015-10-27 |
2017-05-04 |
Eupraxia Pharmaceuticals Inc. |
Sustained release formulations of local anesthetics
|
HUE069590T2
(hu)
|
2019-01-18 |
2025-03-28 |
Astrazeneca Ab |
PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások
|